NAMA
RXRX icon

Nikko Asset Management Americas’s Recursion Pharmaceuticals RXRX Stock Holding History

Nikko Asset Management Americas’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.6M Sell
5,419,221
-801,804
-13% -$3.1M 0.23% 71
2025
Q4 		$25.4M Sell
6,221,025
-1,244,833
-17% -$6.17M 0.29% 67
2025
Q3 		$36.4M Sell
7,465,858
-701,887
-9% -$3.69M 0.35% 62
2025
Q2 		$41.2M Sell
8,167,745
-239,589
-3% -$1.18M 0.41% 51
2025
Q1 		$44.4M Sell
8,407,334
-501,317
-6% -$3.65M 0.57% 46
2024
Q4 		$60.1M Sell
8,908,651
-786,127
-8% -$5.29M 0.65% 40
2024
Q3 		$63.9M Sell
9,694,778
-239,713
-2% -$1.72M 0.72% 38
2024
Q2 		$74.3M Sell
9,934,491
-428,312
-4% -$3.74M 0.86% 31
2024
Q1 		$103M Buy
10,362,803
+1,159,023
+13% +$12.9M 1.02% 29
2023
Q4 		$90.6M Buy
9,203,780
+5,680,656
+161% +$40.5M 0.87% 31
2023
Q3 		$27M Buy
3,523,124
+2,685,724
+321% +$26.8M 0.32% 55
2023
Q2 		$6.25M Buy
837,400
+335,423
+67% +$2.35M 0.07% 105
2023
Q1 		$3.3M Buy
501,977
+47,455
+10% +$376K 0.04% 126
2022
Q4 		$3.5M Sell
454,522
-36,218
-7% -$355K 0.05% 126
2022
Q3 		$5.16M Buy
490,740
+90,839
+23% +$920K 0.07% 112
2022
Q2 		$3.24M Sell
399,901
-15,367
-4% -$103K 0.04% 137
2022
Q1 		$2.82M Buy
415,268
+46,274
+13% +$492K 0.02% 152
2021
Q4 		$6.32M Sell
368,994
-40,200
-10% -$756K 0.03% 128
2021
Q3 		$8.59M Buy
409,194
+173,348
+74% +$4.91M 0.04% 127
2021
Q2 		$8.61M Buy
+235,846
New +$6.98M 0.03% 136

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nikko Asset Management Americas's RXRX Position: Q1 2026 in Review

Nikko Asset Management Americas reduced its Recursion Pharmaceuticals (RXRX) stake by 13% in Q1 2026, selling an estimated $3.1M and leaving 5,419,221 shares worth $16.6M. The position accounts for 0.23% of the portfolio, ranked #71.

Nikko Asset Management Americas first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $103M in Q1 2024. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Nikko Asset Management Americas held 5,419,221 shares of Recursion Pharmaceuticals worth $16.6M as of Q1 2026.
  • Nikko Asset Management Americas sold 801,804 Recursion Pharmaceuticals shares in Q1 2026, an estimated $3.1M.
  • Recursion Pharmaceuticals made up 0.23% of Nikko Asset Management Americas's portfolio in Q1 2026, its #71 holding.
  • Nikko Asset Management Americas first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Nikko Asset Management Americas's Recursion Pharmaceuticals position peaked at $103M in Q1 2024.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Nikko Asset Management Americas's 13F filing for Q1 2026, filed 7 May 2026.